Replies to post #390726 on Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

It’s not up to the world to decide. It’s up to drug regulators. If the data don’t support the company’s statements, the world will thankfully be deprived of a treatment that is not effective.

The veracity of the reported data for AD, Rett, and PDD is what is in serious doubt. The close scrutiny of the data from experts unaffiliated with Anavex, and Missling’s opaqueness, are what are causing serious doubts and concerns, as reflected in the recent stock price collapse.

[FitzyP33]

Yes, right. Anavex is a small, unknown biotech company that doesn't get the benefit of the doubt on anything. Anavex will get turned down because they can't present the data to regulators in a clear, compelling manner. Missling starts out 10 strokes behind big pharma in front of the FDA so he has play perfectly just to catch up. Perhaps he's better with the FDA than he is with analysts, but I doubt it. Bottom line, he has to be perfect. He can't tell the FDA that his way of doing analysis is better than how it's been done before. That may be true, but does he really want to die on that hill and/or wait for the big boys present it his way. Bureaucrats don't like change. Missling will never convince them his way is better. Biogen maybe can.